Skip to main content
×
×
Home

Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy

  • Kee-Hong Choi (a1), Til Wykes (a2) and Matthew M. Kurtz (a3)
Abstract
Background

A growing number of studies have investigated the efficacy of novel, adjunctive pharmacotherapies for treatment of cognitive deficits in schizophrenia with conflicting results.

Aims

To investigate the comparative efficacy of these agents on cognition and symptoms in schizophrenia, and to identify promising cognitive domains and candidate medications that can be incorporated in treatment trials combined with cognitive remediation to maximise treatment effects.

Method

A total of 26 double-blind, placebo-controlled studies investigating medications targeted at cholinergic, glutamatergic or serotonergic receptor classes and with participants with schizophrenia or schizoaffective disorder were identified.

Results

Medications targeted at the cholinergic receptor class produced marginal improvements in verbal learning and memory (d = 0.23, P = 0.06), and donepezil, a specific type of cholinergic agonist, produced a moderate effect (d = 0.58) on spatial learning and memory. Cholinergic and glutamatergic agents produced moderate effect-size improvements on negative symptoms (d = 0.54 and d = 0.62 respectively), and small effect-size improvements on general symptoms (d = 0.46 and d = 0.41 respectively). Serotonergic agents produced small effect-size improvements in positive symptoms (d = 0.33).

Conclusions

Cholinergic medications produced marginal improvement in verbal learning and memory and moderate improvements on spatial learning and memory, although there was no evidence to support the use of glutamatergic or serotonergic medications as a stand-alone treatment for improving cognitive function. Cholinergic and glutamatergic agents improved negative and general symptoms, whereas serotenergic medications improved positive symptoms.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy
      Available formats
      ×
Copyright
Corresponding author
Matthew M. Kurtz, PhD, Department of Psychology, Wesleyan University, Judd Hall, 207 High Street, Middletown, Connecticut 06459, USA. Email: mkurtz@wesleyan.edu
Footnotes
Hide All

These authors contributed equally to this work.

Declaration of interest

None.

Footnotes
References
Hide All
1 Green, MF, Nuechterlein, KH. Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull 1999; 25: 309–19.
2 Saykin, AJ, Shtasel, DL, Gur, RE, Kester, DB, Mozley, LH, Stafiniak, P., et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51: 124–31.
3 Harvey, P., Silverman, J., Mohs, R., Parrella, M., White, L., Powchik, P., et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry 1999; 45: 3240.
4 Green, MF, Kern, RS, Braff, DL, Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 2000; 26: 119–36.
5 Green, MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67: 38.
6 Harvey, PD, Keefe, RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176–84.
7 Keefe, S., Bilder, R., Davis, S., Harvey, P., Palmer, B., Gold, J., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007; 64: 633–47.
8 Wykes, T., Huddy, V., Cellard, C., McGurk, SR, Czobor, P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011; 168: 472–85.
9 Fagerlund, B., S⊘holm, B., Fink-Jensen, A., Lublin, H., Glenth⊘j, BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol 2007; 30: 312.
10 Friedman, JI, Adler, DN, Howanitz, E., Harvey, PD, Brenner, G., Temporini, H., et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002; 51: 349–57.
11 Keefe, RS, Malhotra, AK, Meltzer, HY, Kane, JM, Buchanan, RW, Murthy, A., et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacol 2008; 33: 1217–28.
12 Kohler, CG, Martin, EA, Kujawski, E., Bilker, W., Gur, RE, Gur, RC. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 2010; 12: 412–21.
13 Sharma, T., Reed, C., Aasen, I., Kumari, V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006; 85: 7383.
14 Buchanan, RW, Conley, RR, Dickinson, D., Ball, MP, Feldman, S., Gold, JM, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008; 165: 82–9.
15 Schubert, MH, Young, KA, Hicks, PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006; 60: 530–3.
16 Lee, SW, Lee, JG, Lee, BJ, Kim, YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 2007; 22: 63–8.
17 Dyer, MA, Freudenreich, O., Culhane, MA, Pachas, GN, Deckersbach, T., Murphy, E., et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008; 102: 8895.
18 Goff, DC, Tsai, G., Manoach, DS, Flood, J., Darby, DG, Coyle, JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153: 1628–30.
19 Tsai, G., Lane, HY, Yang, P., Chong, MY, Lange, N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452–56.
20 Tsai, G., Yang, P., Chung, LC, Lange, N., Coyle, JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44: 1081–9.
21 Buchanan, RW, Javitt, DC, Marder, SR, Schooler, NR, Gold, JM, McMahon, RP, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164: 1593–602.
22 Tsai, GE, Yang, P., Chung, LC, Tsai, I. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156: 1822–5.
23 Tsai, GE, Yang, P., Chang, YC, Chong, MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59: 230–4.
24 Lane, HY, Liu, YC, Huang, CL, Chang, YC, Liau, CH, Perng, CH, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 2008; 63: 912.
25 Sumiyoshi, T., Park, S., Jayathilake, K., Roy, A., Ertugrul, A., Meltzer, HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2007; 95: 158–68.
26 Sumiyoshi, T., Matsui, M., Nohara, S., Yamashita, I., Kurachi, M., Sumiyoshi, C., et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001; 158: 1722–5.
27 Pikuli, D., Olver, JS, Maruff, P., Norman, TR. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5 HT1A receptor agonist. Hum Psychopharm Clin 2009; 24: 437–46.
28 Poyurovsky, M., Koren, D., Gonopolsky, I., Schneidman, M., Fuchs, C., Weizman, A., et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol 2003; 13: 123–8.
29 de Gracia Dominguez, M., Viechtbauer, W., Simons, CJP, van Os, J., Krabbendam, L. Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol Bull 2009; 135: 157–71.
30 Moher, D., Cook, DJ, Eastwood, S., Olkin, I., Rennie, D., Stroup, DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354: 1896–900.
31 Goff, DC, Hill, M., Barch, D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav 2011; 99: 245–53.
32 Nuechterlein, KH, Barch, DM, Gold, JM, Goldberg, TE, Green, MF, Heaton, RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 72: 2939.
33 McGurk, SR, Twamley, EW, Sitzer, DI, McHugo, GJ, Mueser, KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007; 164: 1791–802.
34 Gladsjo, JA, McAdams, LA, Palmer, BW, Moore, DJ, Jeste, DV, Heaton, RK. A six-factor model of cognition in schizophrenia and related psychotic disorders: relationships with clinical symptoms and functional capacity. Schizophr Bull 2004; 30: 739–54.
35 Glass, GV. Integrating findings: the meta-analysis of research. Rev Res Educ 1977; 5: 351–79.
36 Rosenthal, R. Parametric measures of effect size. In The Handbook of Research Synthesis (eds Cooper, HM, Hedges, LV): 231–44. Sage, 1994.
37 Lipsey, MW, Wilson, DB. The way in which intervention studies have “personality” and why it is important to meta-analysis. Eval Health Prof 2001; 24: 236–54.
38 Glass, GV, McGaw, B., Smith, ML. Meta-analysis in Social Research. Sage, 1981.
39 Hedges, LV, Vevea, JL. Fixed-and random-effects models in meta-analysis. Psychol Methods 1998; 3: 486504.
40 Hedges, LV, Olkin, I. Statistical Methods for Meta-Analysis. Academic Press, 1985.
41 Hedges, LV. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Stat 1981; 6: 107–28.
42 Orwin, RG. A fail-safe N for effect size in meta-analysis. J Educ Stat 1983; 8: 157–9.
43 Kohler, CG, Walker, JB, Martin, EA, Healey, KM, Moberg, PJ. Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr Bull 2010; 36: 1009–19.
44 Akhondzadeh, S., Gerami, M., Noroozian, M., Karamghadiri, N., Ghoreishi, A., Abbasi, SH, et al. A 12-week, double-blind, placebo– controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1810–5.
45 Freudenreich, O., Herz, L., Deckersbach, T., Evins, AE, Henderson, DC, Cather, C., et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2005; 181: 358–63.
46 Lindenmayer, JP, Khan, A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 2011; 125: 267–77.
47 Lee, BJ, Lee, JG, Kim, YH. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol 2007; 21: 421–7.
48 Schubert, MH, Young, KA, Hicks, PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006; 60: 530–3.
49 Goff, DC, Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, DA, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56: 21–7.
50 Goff, DC, Cather, C., Gottlieb, JD, Evins, AE, Walsh, J., Raeke, L., et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106: 320–7.
51 Goff, DC, Leahy, L., Berman, I., Posever, T., Herz, L., Leon, AC, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484–7.
52 Goff, DC, Lamberti, JS, Leon, AC, Green, MF, Miller, AL, Patel, J., et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacol 2008; 33: 465–72.
53 Sumiyoshi, T., Matsui, M., Yamashita, I., Nohara, S., Kurachi, M., Uehara, T., et al. The effect of tandospirone, a serotonin (1A) agonist, on memory function in schizophrenia. Biol Psychiatry 2001; 49: 861–8.
54 Shiina, A., Shirayama, Y., Niitsu, T., Hashimoto, T., Yoshida, T., Hasegawa, T., et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry 2010; 9: 110.
55 Keefe, RSE, Buchanan, RW, Marder, SR, Schooler, NR, Dugar, A., Zivkov, M., et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 2013; 39: 417–35.
56 Wykes, T., Spaulding, WD. Thinking about the future cognitive remediation therapy – what works and could we do better? Schizophr Bull 2011; 37 (suppl 2): S8090.
57 Keefe, RSE, Fox, KH, Harvey, PD, Cucchiaro, J., Siu, C., Loebel, A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 2011; 125: 161–8.
58 Keefe, RSE, Goldberg, TE, Harvey, PD, Gold, JM, Poe, MP, Coughenour, L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004; 68: 283–97.
59 Nuechterlein, KH, Green, MF, Kern, RS, Baade, LE, Barch, DM, Cohen, JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008; 165: 203–13.
60 Hawkins, KA, Wexler, BE. California Verbal Learning Test practice effects in a schizophrenia sample. Schizophr Res 1999; 39: 73–8.
61 Dickinson, D., Harvey, PD. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull 2009; 35: 403–14.
62 Amminger, GP, Schäfer, MR, Papageorgiou, K., Klier, CM, Cotton, SM, Harrigan, SM, et al. Long-chain-3 fatty acids for indicated prevention of psychotic disorders. Arch Gen Psychiatry 2010; 67: 146–54.
63 Javitt, DC. Effects of intranasal AL-108 (davunetide) on neurocognition and functional outcome in schizopherenia. Schizophr Res 2010; 117: 118–9.
64 Green, MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321–30.
65 Gleser, LJ, Olkin, I. Stochastically dependent effect sizes. In The Handbook of Research Synthesis (eds Cooper, HM, Hedges, LV): 339–55. Sage Publications, 1994.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×
Type Description Title
PDF
Supplementary materials

Choi et al. supplementary material
Supplementary Table S1-S3

 PDF (144 KB)
144 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 17 *
Loading metrics...

Abstract views

Total abstract views: 85 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 20th April 2018. This data will be updated every 24 hours.

Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy

  • Kee-Hong Choi (a1), Til Wykes (a2) and Matthew M. Kurtz (a3)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *